Vascular Disease Management

A New Kid in Town: Single-Session Treatment for Iliofemoral DVT Without Thrombolytics

IThis article first appeared in Cath Lab Digest, Volume 27 – Issue 12 – December 2019. liofemoral deep venous thrombosis (DVT) causes venous outflow obstruction associated with severe symptoms of pain and swelling. This article first appeared in Cath Lab Digest, Volume 27 – Issue 12 – December 2019. 

Four-Year Data Show Long-Term Durability for EndoSuture Aneurysm Repair in Hostile Necks

Four-year follow-up data from the ANCHOR registry, which captures long-term outcomes of ESAR (EndoSuture Aneurysm Repair) with the Heli-FX EndoAnchor System (Medtronic) and commercially available grafts, was presented by William Jordan Jr., MD, Professor of Surgery and Chief, Division of Vascular Surgery and Endovascular Therapy at Emory University School of Medicine and Jean-Paul de Vries, MD, currently Chair of the Department of Surgery at University Medical Center Groningen, in Groningen, […]

Apple Core: A Novel Technique for Accessing Calcified and Fibrotic Common Femoral Arteries

This article originally appeared in Cath Lab Digest, Volume 27 – Issue 11 – November 2019.  Severe peripheral arterial disease can contribute tremendous difficulty to cardiac procedures.

How to Prepare For, and Treat, Potential Complications in the Outpatient Endovascular Center

Working in an outpatient endovascular center, also known as an office-based lab (OBL), prompts certain considerations that do not exist in a hospital setting.

Two-Year Results of IMPERIAL: First-Ever Randomized Study of Eluvia and Zilver PTX in Femoropopliteal Artery Lesions

IMPERIAL is a global, randomized, controlled trial (n=465) comparing the Eluvia paclitaxel-eluting nitinol stent (Boston Scientific) with the Zilver PTX paclitaxel-coated stent (Cook Medical) for treatment of femoropopliteal artery lesions.

Multilevel CTO Crossing and Treatment

Critical limb ischemia (CLI) is associated with high morbidity and mortality. In untreated individuals, mortality has been estimated to be as high as 54% after only one year.

Defining Critical Limb Ischemia

Critical limb ischemia (CLI) is a heterogeneous disease that is not well understood. Current evaluation and treatment paradigms lack rigorous clinical trial data to support their broad application.